NOVEL FORMS OF BRAIN STIMULATION & PSYCHEDELIC ASSISTED PSYCHOTHERAPY
With
Professor Paul Fitzgerald,
Director, School of Medicine and Psychology,
Australian National University, Canberra, Australia &
Principal Investigator, Paratus Clinical, Australia
RESEARCHER PROFILE
Filmed in Canberra, Australia | November 2025
Professor Paul Fitzgerald is the Head of the School of Medicine and Psychology at the Australian National University. He is an academic psychiatrist with a MBBS degree, Masters of Psychological Medicine and research PhD.
He has conducted an extensive range of experimental studies and clinical trials, focused on the development of novel treatment options for patients with mental health conditions such as depression, schizophrenia, obsessive compulsive disorder, PTSD, autism and Alzheimer’s disease.
Professor Fitzgerald has a special interest in repetitive transcranial magnetic stimulation (rTMS) and other novel treatments using forms of non-invasive brain stimulation. He has had continual NHMRC grant support for 20 years and over $10 million in research support in the last 5 years. He has published several books, over 550 journal articles and been cited over 30,000 times.
He has established multiple clinical rTMS services, founded several device and clinical service companies and led a national application to MSAC in the Federal Department of Health which resulted, in 2021, in Medicare funding ($280 million in year 1) for rTMS therapy for patients with depression.
Professor Fitzgerald currently leads an innovative school at the ANU which combines both the ANU Medical Program and former Research School of Psychology focussed on education and research approaches integrating perspectives across mind, body and culture.
Source: Supplied
https://orcid.org/0000-0003-4217-8096
-
Mechanisms of resistance to menin inhibitor therapy and Acute Myeloid Leukaemia
Dr Rithin Nedumannil (MBBS, MPH, FRACP, FRCPA) is a PhD candidate at the University of Melbourne, undertaking his doctoral studies in collaboration with the Cambridge Stem Cell Institute (Cambridge, UK) and the Peter MacCallum Cancer Centre (Melbourne, Australia). He is a clinical haematologist and haematopathologist with current appointments at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, Austin Health and Northern Health.
-
Superslayer taking on antibiotic-resistant bacteria
Dr Katharina Richter is a visionary leader in MedTech, acclaimed for innovation and gender diversity. With over 40 awards to her name, including MIT Innovator Under 35 Asia-Pacific, and Prime Minister’s Prize for New Innovator finalist, she has shattered barriers as an entrepreneur, scientist, and ‘superbug slayer.’ Katharina’s groundbreaking work in combating antibiotic-resistant bacteria has resulted in 6 innovative treatments, 3 of which are patented, offering hope against deadly infections.
-
Pancreatic and lung cancers driven by mutations in the cancer gene KRAS
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).
